Literature DB >> 26800771

Using postoperative SNOT-22 to help predict the probability of revision sinus surgery.

Luke Rudmik1, Zachary M Soler2, Claire Hopkins3.   

Abstract

BACKGROUND: There is a need to develop a patient-level strategy to identify those at higher risk of requiring revision ESS since this may assist clinicians in tailoring their postoperative management. This study evaluated whether identifying changes in the post- operative 22-item Sinonasal Outcome Test (SNOT-22) can help identify patients at increased risk of needing revision sinus surgery for refractory chronic rhinosinusitis (CRS).
METHODS: 668 CRS patients undergoing primary ESS with complete 60-month follow-up were evaluated in this prospective, longitudinal cohort study. Outcomes were evaluated in an unselected cohort and a low-risk cohort, which was comprised of patients without a history of asthma or aspirin sensitivity.
RESULTS: Failing to achieve an improvement of greater than one minimal clinically important difference (MCID; 9 points) at 3 months after primary ESS and a deterioration of greater than one MCID (ie. >9 points) from the 3- to 12-month follow-up periods was associated with an increased risk of revision ESS in both the unselected and low-risk CRS cohorts.
CONCLUSION: Outcomes from this study suggest that identifying MCID changes in the SNOT-22 score within 12 months after primary ESS can identify patients at increased risk for needing revision surgery.

Entities:  

Mesh:

Year:  2016        PMID: 26800771     DOI: 10.4193/Rhino15.284

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  8 in total

Review 1.  Economics of Chronic Rhinosinusitis.

Authors:  Luke Rudmik
Journal:  Curr Allergy Asthma Rep       Date:  2017-04       Impact factor: 4.806

2.  Evaluating Surgeon-Specific Performance for Endoscopic Sinus Surgery.

Authors:  Luke Rudmik; Yuan Xu; Jeremiah A Alt; Adam Deconde; Timothy L Smith; Rodney J Schlosser; Hude Quan; Zachary M Soler
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-09-01       Impact factor: 6.223

3.  The link between chronic rhinosinusitis and asthma: A questionnaire-based study.

Authors:  Chien-Chia Huang; Chun-Hua Wang; Chia-Hsiang Fu; Chi-Che Huang; Po-Hung Chang; I-Wei Chen; Ta-Jen Lee
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

4.  Factors Affecting the Control of Chronic Rhinosinusitis With Nasal Polyps: A Comparison in Patients With or Without NERD.

Authors:  Markus Jukka Lilja; Anni Koskinen; Paula Virkkula; Seija Inkeri Vento; Jyri Myller; Sari Hammarén-Malmi; Anu Laulajainen-Hongisto; Maija Hytönen; Antti Mäkitie; Jura Numminen; Saara Sillanpää; Hannu Raitiola; Markus Rautiainen; Sanna Katriina Toppila-Salmi
Journal:  Allergy Rhinol (Providence)       Date:  2021-04-26

5.  Dysregulated Maresin Concentrations in Plasma and Nasal Secretions From Patients With Chronic Rhinosinusitis.

Authors:  Issa Beegun; Duco S Koenis; Ghassan Alusi; Jesmond Dalli
Journal:  Front Immunol       Date:  2021-08-31       Impact factor: 7.561

6.  Assessing Cut-off Points of Eosinophils, Nasal Polyp, and Lund-Mackay Scores to Predict Surgery in Nasal Polyposis: A Real-World Study.

Authors:  P Virkkula; E Penttilä; S I Vento; J Myller; A Koskinen; S Hammarén-Malmi; A Laulajainen-Hongisto; M Hytönen; M Lilja; J Numminen; S Sillanpää; J Sahlman; S Toppila-Salmi
Journal:  Allergy Rhinol (Providence)       Date:  2020-10-19

7.  Using machine learning for the personalised prediction of revision endoscopic sinus surgery.

Authors:  Mikko Nuutinen; Jari Haukka; Paula Virkkula; Paulus Torkki; Sanna Toppila-Salmi
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.752

8.  Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis.

Authors:  Stefania Gallo; Federico Russo; Francesco Mozzanica; Andrea Preti; Francesco Bandi; Cecilia Costantino; Roberto Gera; Francesco Ottaviani; Paolo Castelnuovo
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.